283 related articles for article (PubMed ID: 19047118)
21. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
Han SW; Oh DY; Im SA; Park SR; Lee KW; Song HS; Lee NS; Lee KH; Choi IS; Lee MH; Kim MA; Kim WH; Bang YJ; Kim TY
Cancer Sci; 2010 Mar; 101(3):793-9. PubMed ID: 20047592
[TBL] [Abstract][Full Text] [Related]
23. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status].
Ge FJ; Liu JZ; Li SS; Wang Y; Liu LJ; Yao K; Zhao CH; Fu YL; Lin L; Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):273-6. PubMed ID: 23985255
[TBL] [Abstract][Full Text] [Related]
25. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.
Zhang W; Winder T; Ning Y; Pohl A; Yang D; Kahn M; Lurje G; LaBonte MJ; Wilson PM; Gordon MA; Hu-Lieskovan S; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Ann Oncol; 2011 Jan; 22(1):104-109. PubMed ID: 20603437
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.
Di Fiore F; Blanchard F; Charbonnier F; Le Pessot F; Lamy A; Galais MP; Bastit L; Killian A; Sesboüé R; Tuech JJ; Queuniet AM; Paillot B; Sabourin JC; Michot F; Michel P; Frebourg T
Br J Cancer; 2007 Apr; 96(8):1166-9. PubMed ID: 17375050
[TBL] [Abstract][Full Text] [Related]
27. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number.
Italiano A; Follana P; Caroli FX; Badetti JL; Benchimol D; Garnier G; Gugenheim J; Haudebourg J; Keslair F; Lesbats G; Lledo G; Roussel JF; Pedeutour F; François E
Ann Surg Oncol; 2008 Feb; 15(2):649-54. PubMed ID: 17987340
[TBL] [Abstract][Full Text] [Related]
28. A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.
Wierzbicki R; Jonker DJ; Moore MJ; Berry SR; Loehrer PJ; Youssoufian H; Rowinsky EK
Invest New Drugs; 2011 Feb; 29(1):167-74. PubMed ID: 19830388
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC).
Stoehlmacher-Williams J; Obermann L; Ehninger G; Goekkurt E
Anticancer Res; 2012 Feb; 32(2):421-5. PubMed ID: 22287728
[TBL] [Abstract][Full Text] [Related]
30. Molecular determinants of cetuximab efficacy.
Vallböhmer D; Zhang W; Gordon M; Yang DY; Yun J; Press OA; Rhodes KE; Sherrod AE; Iqbal S; Danenberg KD; Groshen S; Lenz HJ
J Clin Oncol; 2005 May; 23(15):3536-44. PubMed ID: 15908664
[TBL] [Abstract][Full Text] [Related]
31. [Cetuximab (Erbitux)].
Shimoyama T
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1203-12. PubMed ID: 19620819
[TBL] [Abstract][Full Text] [Related]
32. Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.
Lai CY; Sung FC; Hsieh LL; Tang R; Chiou HY; Wu FY; Yeh CC
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S599-606. PubMed ID: 23800895
[TBL] [Abstract][Full Text] [Related]
33. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer.
Galal KM; Khaled Z; Mourad AM
Indian J Cancer; 2011; 48(1):47-54. PubMed ID: 21248446
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience.
Pantelic A; Markovic M; Pavlovic M; Jancic S
J BUON; 2016; 21(1):70-9. PubMed ID: 27061533
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Mo Z; Gao F
Colorectal Dis; 2010 May; 12(5):399-406. PubMed ID: 19508512
[TBL] [Abstract][Full Text] [Related]
36. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.
Allegra CJ; Rumble RB; Hamilton SR; Mangu PB; Roach N; Hantel A; Schilsky RL
J Clin Oncol; 2016 Jan; 34(2):179-85. PubMed ID: 26438111
[TBL] [Abstract][Full Text] [Related]
37. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
[TBL] [Abstract][Full Text] [Related]
38. FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease.
Sclafani F; Gonzalez de Castro D; Cunningham D; Hulkki Wilson S; Peckitt C; Capdevila J; Glimelius B; Roselló Keränen S; Wotherspoon A; Brown G; Tait D; Begum R; Thomas J; Oates J; Chau I
Clin Cancer Res; 2014 Sep; 20(17):4511-9. PubMed ID: 24987061
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
Maubec E; Petrow P; Scheer-Senyarich I; Duvillard P; Lacroix L; Gelly J; Certain A; Duval X; Crickx B; Buffard V; Basset-Seguin N; Saez P; Duval-Modeste AB; Adamski H; Mansard S; Grange F; Dompmartin A; Faivre S; Mentré F; Avril MF
J Clin Oncol; 2011 Sep; 29(25):3419-26. PubMed ID: 21810686
[TBL] [Abstract][Full Text] [Related]
40. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
Personeni N; Fieuws S; Piessevaux H; De Hertogh G; De Schutter J; Biesmans B; De Roock W; Capoen A; Debiec-Rychter M; Van Laethem JL; Peeters M; Humblet Y; Van Cutsem E; Tejpar S
Clin Cancer Res; 2008 Sep; 14(18):5869-76. PubMed ID: 18794099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
